share_log

RBC Capital Maintains Outperform on OptimizeRx, Raises Price Target to $17

Benzinga ·  Jan 10 23:03

RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:OPRX) with a Outperform and raises the price target from $14 to $17.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment